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Secondary hypertension refers to arterial hypertension due to an identifiable cause and affects5–10% of the general hypertensive population.
Because secondary forms are rare and work up is time-consuming and expensive, only patients with clinical suspicion should be screened. In
recent years, some new aspects gained importance regarding this screening. In particular, increasing evidence suggests that 24 h ambulatory
blood pressure (BP) monitoring plays a central role in the work up of patients with suspected secondary hypertension. Moreover, obstructive
sleep apnoea has been identified as one of the most frequent causes. Finally, the introduction of catheter-based renal denervation for the treat-
ment of patientswith resistant hypertension has dramatically increased the interest and the numberof patients evaluated for renal artery stenosis.
We review the clinical clues of the most common causes of secondary hypertension. Specific recommendations are given as to evaluation and
treatment of various forms of secondary hypertension. Despite appropriate therapy or even removal of the secondary cause, BP rarely ever
returns to normal with long-term follow-up. Such residue hypertension indicates either that some patients with secondary hypertension also
have concomitant essential hypertension or that irreversible vascular remodelling has taken place. Thus, in patients with potentially reversible
causes of hypertension, early detection and treatment are important to minimize/prevent irreversible changes in the vasculature and target
organs.
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Introduction
Secondary hypertension is defined as increased systemic blood pres-
sure (BP) due to an identifiable cause.Only 5–10%of patients suffer-
ing from arterial hypertension have a secondary form, whereas the
vast majority has essential (idiopathic or primary) hypertension.1
Because secondary forms are rare and screening for them expensive
and laborious, it is not costeffective to search for secondary causesof
hypertension in every patient.
Moreover, while the majority of young patients (,40 years old)
with secondary hypertension respond to specific treatment, in
.35% of elderly patients target BP values are not achieved even
after specific treatment.2 This suggests that on the one side, early de-
tection and treatment of secondary hypertension are important to
minimize irreversible changes in the systemic vasculature,3 on the
other side, the prevalence of concomitant primary and secondary
hypertension rises with increasing age.2
The aim of this review is to give indications which hypertensive
patients should be screened for secondary forms and the tests to
be used.
Prevalence
The prevalence of secondary hypertension depends mostly on age
and clinical characteristics of the screened population.4–7 We
should remember that ‘essential’ hypertension is not less common
in patients who have secondary hypertension than in the general
population. Thus, not uncommonly there remains some residue
hypertension after the pathogenetic cause of secondary hyperten-
sion has been identified and removed. In patients with resistant
hypertension, defined as increased BP despite the use of three anti-
hypertensive drugs including a diuretic at the optimal dosages, the
prevalence of secondary forms is significantly higher than in patients
with controlled BP (Table 1).8
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Table 1 Overview of the most common causes for secondary hypertension
Secondary cause Prevalencea Prevalenceb History Screening Clinical findings Laboratory findings
Obstructive sleep
apnoea
.5–15% .30% Snoring, daytime sleepiness,
morning headache, irritability
Screening questionnaire;
polysomnography
 neck circumference; obesity; peripheral
oedema
Not specific
Renal parenchymal
disease
1.6–8.0% 2–10% Loss of good BP-control; diabetes;
smoking; generalized
atherosclerosis; previous renal
failure; nocturia
Creatinine, ultrasound of the
kidney
Peripheral oedema; pallor; loss of muscle mass  Creatinine, proteinuria; 
Ca2+,  K+,  PO4
Renal artery stenosis 1.0–8.0% 2.5–20% Generalized atherosclerosis;
diabetes; smoking; recurrent
flush pulmonary oedema
Duplex, or CT, or MRI, or
angiography (drive by)
Abdominal bruits; peripheral vascular disease; Secondary aldosteronism:
ARR;  K+;  Na+
Primary aldosteronism 1.4–10% 6–23% Fatigue; constipation; polyuria,
polydipsia
Aldosterone–renin ratio
(ARR)
Muscle weakness  K+; ARR 
Thyroid disease 1–2% 1–3% Hyperthyreoidism; palpitations,
weight loss, anxiety, heat
intolerance; Hypothyreodism;
weight gain, fatigue, obstipation
TSH Hyperthyreodism: tachycardia, AF; accentuated
heart sounds; exophthalmus; Hypothyreodism;
Bradycardia; muscle weakness; myxoedema
Hyperthyreodism: TSH; fT4
and/or fT3 ;
Hypothyreodism: TSH ;
fT4 ; cholesterol 
Cushing’s Syndrome 0.5% ,1.0% Weight gain; impotence; fatigue;
psychological changes;
polydypsia and polyuria
24 h urinary cortisol;
dexamethasone testing
Obesity, hirsutism, skin atrophy, Striae rubrae,
muscle weakness, osteopenia
24 h urinary; cortisol ;
Glucose; Cholesterol ;
K+
Phaeochromocytoma 0.2–0.5% ,1% Headache; palpitations; flushing;
anxiety
Plasma-metanephrines; 24 h
urinary catecholamine
The 5 ‘Ps’c: paroxysmal hypertension; pounding
headache; perspiration; palpitations; pallor
metanephrines 
Coarctation of the
aorta
,1% ,1% Headache; nose bleeding; leg
weakness or claudicatio
Cardiac ultrasound Different BP (≥20/10 mmHg) between upper–
lower extremities and/or between right– left
arm;  and delayed femoral pulsations;
interscapular ejection murmur; rib notching
on chest Rx
Not specific
BP, blood pressure; Ca2+, calcium; K+, potassium; PO4, phosphate; CT, computer tomography; ARR, aldosterone–renin ratio; Na
+, sodium; AF, atrial fibrillation; TSH, thyroid-stimulating hormone; fT4, free thyroxine; fT3, free triiodothyronine.
aPrevalence in hypertensive patients.
bPrevalence in patients with resistant hypertension.
cKaplan’s, Clinical hypertension, Tenth Edition, 2010, Lippincott Williams &Wilkins, p. 363.
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In children and adolescents, the most common causes for hyper-
tension are renal parenchymal or vascular disease and aortic coarc-
tation.9 In adults, earlier studies identified renal parenchymal and
vascular disease as themost common causes of secondary hyperten-
sion.More recently, obstructive sleep apnoea (OSA)was recognized
as an exceedingly common cause of secondary hypertension
(Table 1).10 Of the endocrine causes associated with hypertension,
primary aldosteronism is the most common, followed by thyroid
disease (hypo- or hyperthyreoidism), hypercortisolism (Cushing’s),
and finally phaeochromocytoma.
Who should be screened?
General clinical characteristics suggestive
of secondary hypertension
At the initial evaluation of a hypertensive patient, it is important to
identify some general clinical clues that could suggest the presence
of a secondary form of hypertension (Table 2; Figure 1).
Age
The most common causes of hypertension in prepubertal children
are renal parenchymal or vascular disease and aortic coarctation.9
Young adults (,30 years) without a family history or other risk
factors for hypertension should undergo screening for secondary
forms. In elderly adults with known atherosclerosis, the presence
of severe hypertension or an acute increase of BP is suggestive for
a secondary form [i.e. renal artery stenosis (RAS)].
Habitus
Overweight patients with resistant hypertension should be screened
for OSA (see below) and endocrine forms of hypertension (i.e.
Cushing, hypothyroidism).
Blood pressure
Patients with resistant hypertension despite adequate drug therapy,
severe hypertension at presentation (.180/110 mmHg), or hyper-
tensive emergencies5 should be screened for a secondary form.
The absence of a nighttime drop in BP (‘dipping’) of .10% relative
to the daytime value during ambulatory BP monitoring (ABPM) was
found to be associatedwith several secondary formsof hypertension
(i.e. OSA, RAS, etc.).11,12 Therefore non-dippers (or even more so
reverse nocturnal dippers) should undergo screening for secondary
forms.
Generalized atherosclerosis
Roughly 15–30% of patients with arterial hypertension and diffuse
atherosclerotic disease (i.e. coronary, peripheral, cerebrovascular
disease) have a significant RAS (defined as≥50%).13,14 The presence
of resistant hypertension, the sudden increase of a previously well-
controlled arterial hypertension or non-dipping are all suggestive
of a relevant RAS.
‘Second diagnostic look’ after starting antihypertensive
therapy
There are some situations thatmay suggest the presenceof a second-
ary hypertension after starting antihypertensive therapy. A second
diagnostic look is indicated if there is:
(1) an excessive drop in potassium with a small dose of a diuretic
(primary aldosteronism or other endogenous or exogenous
mineralocorticoid excess)
(2) Excessive decrease in GFRwith a small dose of an ACE-inhibitor
(RAS, predominately when bilateral)
(3) a remarkably resistant arterial hypertension
Table 2 General clinical characteristics suggestive of
secondary hypertension
Early onset of hypertension (i.e. ,30 years) in patients without other
risk factors (i.e. family history, obesity, etc.); increased BP in
prepubertal children
Resistant hypertension (.140/90 mmHg despite three
antihypertensive drugs including a diuretic)
Severe hypertension (.180/110 mmHg) or hypertensive emergencies
Sudden increase of BP in a previously stable patient
Non-dipping or reverse dipping during 24 h ambulatory BP monitoring
Presence of target organ damage (i.e. LVH, hypertensive retinopathy,
etc.)
BP, blood pressure; LVH, left ventricular hypertrophy.
Figure 1 Work-up in patients with suspected secondary hyper-
tension. 24 h-ABPM, 24 h ambulatory blood-pressure monitoring.
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(4) bloodpressuredecreaseswith treatment but remains excessive-
ly labile
What to do before screening: exclude
pseudo-hypertension and
pseudo-resistance
Patients with resistant arterial hypertension should be screened for
secondary forms.8 However, before starting the screening, pseudo-
hypertension and pseudo-resistance should be excluded.8
Pseudo-hypertension
Pseudo-hypertension is defined as cuff diastolic BP at least 15 mmHg
higher than simultaneously measured intra-arterial BP. It is found in
elderly patients with calcified and rigid arteries who present with
little or no target organ damage despite very high BP readings. In
these patients, excessive cuff pressure is needed to compress the
artery resulting in falsely high readings. This entity may be identified
using the Osler manoeuvre.15 However, this manoeuvre has a large
intra- and inter-observer variability.16 Assessment of brachial arterial
stiffness by measurement of carotid-radial pulse wave velocity may
also help identify patientswith this particular formof hypertension.16
Pseudo-resistance: inadequate blood pressure
measurement techniques
There are two very common causes for pseudo-resistance due to in-
accurate BP measurement techniques: (i) BP measurement without
letting the patient quietly sit for at least 5 min and (ii) inadequate
cuff size (too small cuff size may result in falsely increased BP
.15 mmHg).17
Poor treatment control
Poor therapy control is sometimes related to physician’s ‘clinical
inertia’, i.e. they fail to up titrate therapy in order to reach target
BP. Conversely, poor patient adherence to therapy is widespread
reaching about 40% in patientswith newly diagnosed hypertension.18
White coat hypertension
White coat hypertension is a frequent cause of pseudo-resistance
with a prevalence of about 20–30%.19 Twenty-four hour ABPM is
a valuable tool to assess the likelihood of secondary hypertension.
Drug-related hypertension
Several medications are related to treatment resistance.20 The most
common are NSAIDs and glucocorticoids probably via sodium and
fluid retention particularly in patients with kidney disease. NSAIDs
may increase mean 24 h systolic BP by 4–5 mmHg, particularly in
patients with pre-existing hypertension and in salt-sensitive
patients.21 Therefore, in patients with hypertension, acetaminophen
is recommended as analgesic of choice.However, a very recent study
showed that even treatment with acetaminophen was associated
with increased 24 h systolic and diastolic BP (2.9 and 2.2 mmHg, re-
spectively, vs. placebo) in patients with coronary artery disease.22
Diet pills (i.e. phenylpropanolamine and sibutramine), stimulants
(i.e. amphetamines and cocaine), and decongestants (i.e. phenyleph-
rine hydrochloride and naphazoline hydrochloride) increase BP via
activation of the sympathetic nervous system; to note, cocaine use
is associated with acute, but not chronic hypertension. Licorice
increases BP via stimulationof themineralocorticoid receptor and in-
hibition of cortisol metabolism.23
Oral contraceptives (oestrogen + progestin) induce hyperten-
sion in about 5% of women.24 The increase in usually small,
however, severe hypertensive episodes may occur.
Antidepressant agents (i.e. venlaflaxine and monoamine oxidase
inhibitors) increase BP in a dose-dependent manner, probably via
noradrenergic stimulation.
Immunosuppressive agents, particularly cyclosporine A, increase
BP by sympathetic activation25 and direct vasoconstriction. Tacroli-
mus has less and rapamycin has almost no effect on BP.
Inhibitors of vascular endothelial growth factor (VEGFi) (i.e. beva-
cizumab, Avastinw) or tyrosine kinase inhibitors (i.e. sunitinib,
Sutentw, sorafenib, Nexavarw) have been reported to increase BP.
This adverse effect has to be considered a class-adverse effect of anti-
angiogenic drugs.Mechanisms involved in the development of hyper-
tension include decrease in nitric oxide bioavailability, rarefaction of
the microvascular bed, and activation of endothelin-1 synthesis, one
of the most potent vasoconstrictors.26,27
With Bevacizumab (Avastinw), the first drug of this class intro-
duced in 2004 for the treatment of colorectal cancer, breast
cancer, and renal cell carcinoma, the incidence of hypertension is
dose related. Patients treated with bevacizumab may have a five-fold
higher incidence of severe hypertension (i.e. .200/100 mmHg)
compared with placebo.28,29 After 6 months of treatment with bev-
acizumab, SBP increased from129 to 145 mmHg and inDBP from75
to 82 mmHg.27
In a recentmeta-analysis, the incidenceof hypertension and severe
hypertension in patients receiving sunitinib (Sutentw) was 21.6 and
6.8%, respectively.30 In the samemeta-analysis, treatment with Sora-
fenib (Nexavarw) was associated with an incidence of hypertension
and severe hypertension of 23.4 and 5.7%, respectively.30
Hypertension associated with VEGFi is often transient and
resolves with discontinuation of the drug. There are no data avail-
able to recommend a specific first-line antihypertensive drug in this
situation.
Role of ambulatory 24 h blood pressure
monitoring
Ambulatory BP monitoring is the best measurement method to
assess arterial BP.12 Ambulatory BP monitoring has a central role if
a secondary form of arterial hypertension is suspected since it allows
to exclude white coat hypertension, assess treatment-adherence,
confirm the presence of resistant hypertension, and assess the
dipping status (Figure 2). While reference values for office BP mea-
surements aim to distinguish between normotensive and hyperten-
sive subjects and are therefore ‘diagnostic’ cut-off values, reference
values for 24 h ABPM in adults have been defined as outcome-driven
thresholds and are considerably lower than clinical ones
(Table 3).1,31,32 In children and adolescents, thresholds are based
on population distribution.32
The presence of reverse nocturnal dipping eventually associated
with increased heart rate is suggestive of the presence of a secondary
form (i.e. OSA, RAS). Of note, sleep deprivation by cuff inflation
during nocturnal BP monitoring may result in impaired or even
reverse dipping.33
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Role of echocardiography
Echocardiography is an important diagnostic tool in patients with
(suspected) secondary hypertension. In particular, the presence of
left ventricular hypertrophy (LVH) disproportionate to the duration
of hypertensionmay suggest secondary hypertension (i.e. primary al-
dosteronism or renovascular hypertension).3,34 In patients with
OSA, LVH is a very common finding and may be accompanied by
left atrial enlargement and right ventricular hypertrophy.35 Finally,
in young adultswith hypertension, echocardiography is the screening
method of choice for coarctation of the aorta (see below).
How to screen
In the following,wewill describe the screening for themost common
causes of secondary hypertension (Table 1).
Common causes of secondary
hypertension
Obstructive sleep apnoea
Obstructive sleep apnoea has been recognized as one of the most
common causes for secondary hypertension (Figure 3).10,36 It is char-
acterized by recurrent obstructive apnoeas and hypopnoeas caused
by collapse of the upper airways during sleep. The severity of OSA is
classified based on the apnoea–hypopnoea index [AHI, number of
apnoeas plus hypopnoeas per hour of sleep: mild (AHI 5–15), mod-
erate (AHI 16–30), and severe (AHI. 30)].37 Most patients with
OSA complain of exaggerated daytime sleepiness, snoring, morning
headache, lack of concentration, and irritability. Typical clinical
findings are obesity, large neck, and macroglossia. Both nocturnal
(non-dipping) anddaytimeBPare increased. Patientsoftendisplay sig-
nificant tachycardia and/or bradycardia during nighttime (Figure 2),
probably due to increased sympathetic nerve activity and respectively
increased vagal tone.38
Mechanisms proposed to explain the BP elevation in OSA are
increased sympathetic nerve activity39,40 and alterations of the
Figure 2 Ambulatory 24 h blood pressure (BP) monitoring in a patient with newly diagnosed obstructive sleep apnoea. Note the reverse noc-
turnal dipping and the increased heart rate (HR) during nighttime, possibly due to exaggerated sympathetic nervous system activity.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Thresholds values for office, home and
ambulatory blood pressure measurement
Category Systolic (mmHg) Diastolic (mmHg)
Office BP ≥140 ≥90
Home BP ≥135 ≥85
Ambulatory BP
24 h ≥130 ≥80
Daytime (or awake) ≥135 ≥85
Nighttime (or asleep) ≥120 ≥70
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renin–angiotensin–aldosterone system41,42 as a result of recurrent
nocturnal hypoxemia. Moreover, hypoxemia has been associated
with systemic endothelial dysfunction43,44 even in the absence of
traditional CV risk factors,45 possibly mediated by excessive oxida-
tive stress.46,47 Several studies have shown a decrease in nocturnal48
or in both nocturnal and daytimeBP49–51 after successful continuous
positive airway pressure therapy of OSA.
A history of snoring and daytime sleepiness should prompt to
suspect OSA and assess sleepiness using the Epworth Sleepiness
scale.52,53 In this questionnaire, patients have to rate their probability
to fall asleep during eight different situations of daily life [between 0
(would never doze) to 3 (high chance of dozing)]. Patients with an
Epworth score ≥10 (indicating the presence of excessive daytime
sleepiness) and a high clinical suspicion of OSA need to be assessed
by polysomnography.54 We recommend that patients with OSA
undergo echocardiography to assess systolic left and right ventri-
cular function, left ventricular mass, and estimate pulmonary artery
pressure.
Renal parenchymal disease
Renal parenchymal disease is the most common cause of secondary
hypertension in children9 and the second most common cause in
adults.55 Urine analysis (protein, erythrocytes, and leucocytes) and
measurement of serumcreatinine concentration are the best screen-
ing methods. If creatinine concentration and/or urine analysis are
pathologic, a renal ultrasound should be the next step.
Renal artery stenosis
In children and young adults, fibromuscular dysplasia of the renal
artery is one of themost common causes of secondary hypertension
and should be excluded by imaging (screening with duplex ultra-
sound, confirmation by angiography) (Figure 4). If fibromuscular dys-
plasia is detected, other vascular beds (i.e. cerebrovascular) should
be screened.56
In adults, the most common form of renovascular disease is ath-
erosclerotic RAS.13 The prevalence of RAS in a general population
of hypertensivepatients is between1 and8%,57,58whereas in patients
with generalized atherosclerosis its prevalence can be as high as 25–
35%.59 Other clinical clues pointing to RAS in adult patients are: an
abdominal bruit, particularly when diastolic; deterioration of the
renal function with angiotensin converting enzyme inhibitors
(ACE-I) or angiotensin receptor blockers; severe or suddenworsen-
ing of hypertension in smokers or in patients with diabetes; diffuse
atherosclerosis and recurrent flash pulmonary oedema.60,61
Further work up if indicated (Table 4) includes imaging by duplex-
ultrasound, CT, or MRI.62 If screening confirms significant RAS
Figure 3 Medical history, clinical findings, and screening work-up in patients with suspected obstructive sleep apnoea. AHI,
apnoea-hypopnoea-index; 24 h-ABPM, 24 h ambulatory blood-pressure monitoring.
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renal angiographywith haemodynamic assessment to detect a signifi-
cant translesional gradient should be considered.63
After percutaneous (or surgical) treatment of RAS, as long as BP
and renal function (GFR) remain stable and well controlled, no
further exams are necessary. Otherwise, renal perfusion/vessel
patency should be assessed with duplex ultrasonography or MRI.64
Atherosclerotic renal artery stenosis: to screen or not to screen?
Despite substantial improvement in imaging techniques over the past
decade, clinicians have become increasingly reluctant to search for
RAS. A reason for abandoning the diagnostic trajectory is doubt as
to whether treatment of atherosclerotic RAS with angioplasty
confers any benefit to the patient. Several studies have shown that
rates of renal events, major cardiovascular events, and death were
similar in the group assigned to undergo revascularization compared
with the control group that receivedmedical treatmentonly.65More-
over, atherosclerotic RAS may be a complication of a pre-existent
hypertension without a significant contribution to the increased BP
values, and there are no tests with sufficient specificity and sensitivity
to assess the contribution of the stenosis on BP. Its contribution can
only be assessedpost hoc, i.e.when arterial BP is decreasedornormal-
ized after revascularization. We thoroughly agree with the observa-
tion of De Leeuw et al.66 that the search for RAS in patients with
hypertension ismost often an exercise in futility since stenting of ath-
erosclerotic RAS confers little benefit.65 A patient with longstanding
hypertension, an estimated GFR of 30 mL/min, and contralateral
nephrosclerosis is very unlikely to benefit from revascularization.
However, an entity that needs to be considered in this context is
the Pickering Syndrome being defined as flash pulmonary oedema
secondary to bilateral RAS.60,61 Clearly in this situation, urgent revas-
cularization will prove to be lifesaving. Thus practicing physicians
cannot simply ‘forget’ about RAS despite the fact that randomized
trials showed little if any benefit of revascularization in patients
Figure 4 Medical history, clinical findings, and screening work-up in patients with suspected atherosclerotic renal artery stenosis. ACE-I,
angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; 24 h-ABPM, 24 h ambulatory blood-pressuremonitoring; K+, potas-
sium; Na+, sodium.
Table 4 Factors predicting effective revascularization
of renal artery stenosis
Resistant hypertension
Recent onset/progression of (severe) hypertension
Recent renal function deterioration
Acute renal function deterioration during therapy with ACE-I or ARB
Flash pulmonary oedema
RAS, renal artery stenosis; ACE-I, angiotensin converting enzyme inhibitor;
ARB, angiotensin-receptor blocker.
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with longstanding disease. Finally, the recent introduction of
catheter-based renal denervation for the treatment of patients
with resistant hypertension has dramatically increased the interest
and the number of patients evaluated for RAS. At this time, there is
insufficient data on the long-term effects of renal denervation on ar-
terial BP and it remains to be seenhow this newtechniquewill change
the approach to resistant hypertension and RAS.67
Primary aldosteronism
Primary (hyper)aldosteronism (PA),orConn-Syndrome, refers to in-
appropriately high aldosterone synthesis that is independent of the
renin–angiotensin system and cannot be suppressed by sodium
loading (Figure 5). It is characterized by arterial hypertension, sup-
pressed plasma renin activity, and increased adrenal aldosterone se-
cretion. The prevalence of PA is between 1.4 and 23%, depending on
the population investigated andon the selected criteria for its diagno-
sis (higher prevalence in resistant hypertensives). According to a
large prospective study in newly diagnosed hypertensive patients,
the prevalence is about 11% and the most common causes for
primary aldosteronism are aldosterone-producing adenoma (APA;
4.8%) and idiopathic hyperaldosteronism (IHA, 6.4%) or idiopathic
adrenal hyperplasia.68 Glucocorticoid remediable aldosteronism is
a rare form.
Clinical clues are not very specific and only about 40% of patients
with PA have hypokalaemia.69 Other clinical features are resistant
hypertension, muscle weakness, constipation, and fatigue. Hypokal-
aemia may be accompanied by metabolic alkalosis, excessive
urinary sodium excretion, and hypernatraemia. If PA is suspected
the plasma aldosterone-renin ratio (ARR) should be assessed as a
first screening step. Since ARR is affected by several factors such as
antihypertensive medications (Table 5), patients should be prepared
for ARR measurement (Table 6).70 Depending on the method used
for assessing ARR, the cut-off values for the diagnosis of PA vary
(Table 7). If ARR is increased confirmatory tests with sodium
loading or captopril suppression should be performed. There are
several methods for sodium loading testing.70 The shortest and
easiest one is the measurement of plasma aldosterone before and
after i.v. infusion of 2000 mL 0.9% saline over 4 h.71 If the post-
infusion plasma aldosterone concentration is ,5 ng/dL, PA is very
unlikely, if it is .10 ng/dL PA is very likely.72 It is important to note
that the saline infusion test is in general a safe and specific test to
confirm (or exclude) PA, but that it has no place for discriminating
Figure 5 Medical history, clinical findings, and screening work-up in patients with suspected primary aldosteronism. PRA, plasma renin activity;
PAC, plasma aldosterone concentration; ARR, aldosterone–renin ratio; 24 h-ABPM, 24 h ambulatory blood-pressuremonitoring; LV, left ventricu-
lar; K+, potassium; Na+, sodium; Mg2+, magnesium; APA, aldosterone-producing adenoma; IHA, idiopathic hyperaldosteronism.
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between APA and IHA.71 If a confirmatory test is positive, imaging
(CT or MRI) and selective vein sampling to should be performed.
Relying on imaging only may lead to inappropriate treatment of
patients with primary aldosteronism. CT/MRI misdiagnosed the
cause of primary aldosteronism in 37.8% of patients when adrenal
vein sampling was used as the standard test for diagnosing laterality
of aldosterone secretion.73
Uncommon causes of secondary
hypertension
Cushing’s syndrome
Cushing’s syndrome is a rare syndrome affecting ,0.1% of the
general population.74 Patients with this syndrome display a typical
body habitus with obesity, facial plethora, buffalo hump, hirsutism,
and purple striae.75 Hypertension is very common affecting about
80% of patients with Cushing. A 24 h urinary cortisol excretion
.55ug/24 h is suggestive for Cushing. Further work up includes
1 mg dexamethasone suppression test at bedtime with measure-
ment of cortisol plasma concentration the next morning (cut-off
1.8 mg/dL).76
Hyper-/hypothyroidism
Both hyper- and hypothyroidism have been associated with arterial
hypertension. In hypothyroidism, diastolic BP is particularly elevated
since low cardiac output is compensated by peripheral vasoconstric-
tion tomaintain adequate tissue perfusion. In contrast, hyperthyroid-
ism is associated with increased cardiac output and predominately
systolic BP elevation. The best screening test is thyroid-stimulating
hormone plasma concentration.
Phaeochromocytoma
Phaeochromocytoma has a prevalence of about 0.2% in unselected
hypertensive patients. Clinical features are due to the paroxysmal
increase of plasma catecholamines and are characterized by the
‘five P’77:
paroxysmal hypertension;
palpitation;
perspiration;
pallor;
pounding headache.
Screening for phaeochromocytoma should be performed only if
one or more of the following criteria are present: resistant hyper-
tension and hyperadrenergic spells (the ‘five P’); family history of
phaeochromocytoma; genetic syndrome known to be associated
with phaeochromocytoma (MEN 2; von Hippel Lindau, neuro-
fibromatosis), adrenal mass with characteristics consistent with
phaeochromocytoma (i.e. large size .4 cm, cystic and haemor-
rhagic changes).
Twomain screening tests are available: 24 h urine catecholamines
andmetanephrine or plasma fractionatedmetanephrines. Some anti-
hypertensive drugs may have effects on metanephrine plasma levels
(Table 5). If screening is positive, imagingwith abdominal/adrenalMRI
orCT is indicated. If abdominal imaging is negative, scintigraphic local-
ization with 123I-metaiodobenzylguanidine (MIBG) or additional
imaging (i.e. whole body MRI, or others) is indicated.
Coarctation of the aorta
Aortic coarctation is the second most common cause of hyperten-
sion in children and young adults.9 It is characterized by constriction
of the lumen of the aorta usually near the ligamentum arteriosum.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6 Preparation for the measurement of ARRa
Correct hypokalaemia if present and liberalize sodium intake
Change antihypertensive medication to drugs with minimal effects on
ARR:
Verapamil slow-release (90–120 mg twice daily)
Hydralazine (10–12.5 mg twice daily)
Doxazosin (2–8 mg once daily)
Blood sampling:
Collect blood in the mid-morning, after the patient has been out of
bed for at least 2 h and sitting 5–15 min
Avoid stasis and haemolysis
Maintain blood at room temperature
ARR, aldosterone:renin ratio.
aModified after reference (56).
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Table 5 Medications that may affect plasma aldosterone, renin, aldosterone–renin ratio, and metanephrine
Medications Aldosterone Renin ARR Metanephrine
b-Blockers    
Clonidine (a2-agonist)    
a1-Blockers (doxazosin)    
K+-wasting diuretics    
K+-sparing diuretics    
ACE-inhibitors    
ARBs    
Ca2+-blockers    
Aliskiren (direct renin inhibitor)   (PRA);  (DRC)  (PRA);  (DRC) 
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ARR, aldosterone–renin ratio; PRA, plasma renin activity; DRC, direct renin concentration.
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This lesion makes up for about 7% of all cases of congenital heart
disease.78 Frequent symptoms are headache, cold feet, and pain in
the legs during exercise. Clinical clues are arterial hypertension in
the presence of weak femoral pulses. Other typical findings include
systolic murmurs in the front and/or back of the chest and notching
of the posterior ribs (collateral circulation) on a chest radiograph.
Echocardiography is the screening method of choice. Alternatively
CT or MRI may also be performed. Early surgical repair or percutan-
eous balloon angioplasty appears equally effective.79 According to
the current guidelines,80 patients with coarctation need regular
follow-up at least every 2 years in a specialized centre for adult
patients with congenital heart disease. Follow-up should include
echocardiography and assessment of BP (preferably 24 h ABPM
with the cuff placed on the right upper arm). Imaging intervals of
the aorta (preferably with MRI) depend on baseline pathology.
Even less common than coarctation of the thoracic aorta is coarcta-
tion of the abdominal aorta which can give rise to severe hyperten-
sion at an early age.81
Long-term follow-up is recommended for these patients who are
at risk for persistent hypertension and other cardiovascular compli-
cations.81–83
Conclusion
Secondary hypertension affects only 5–10% of the hypertensive
patients. Screening is expensive and time-consuming and should be
performed only in patients with high clinical suspicion. Moreover,
despite having found and appropriately treated a secondary cause
of hypertension, BP rarely ever returns to normal. This indicates
either that some patients with secondary hypertension also have
concomitant essential hypertension or that vascular remodelling
has taken place and progressed over time to the point of no return.
Therefore, in patientswith a potentially reversible cause of hyperten-
sion, early detection and treatment are important to minimize/
prevent irreversible changes in the systemic vasculature which may
give rise to persistent hypertension with an unfavourable long-term
outcome.
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